Cargando…

Detection of circulating tumor cells and circulating tumor DNA before and after mammographic breast compression in a cohort of breast cancer patients scheduled for neoadjuvant treatment

PURPOSE: It is not known if mammographic breast compression of a primary tumor causes shedding of tumor cells into the circulatory system. Little is known about how the detection of circulating biomarkers such as circulating tumor cells (CTCs) or circulating tumor DNA (ctDNA) is affected by breast c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Förnvik, Daniel, Aaltonen, Kristina E., Chen, Yilun, George, Anthony M., Brueffer, Christian, Rigo, Robert, Loman, Niklas, Saal, Lao H., Rydén, Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2019
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6661025/ https://www.ncbi.nlm.nih.gov/pubmed/31236809 http://dx.doi.org/10.1007/s10549-019-05326-5

Ejemplares similares

No evidence for shedding of circulating tumor cells to the peripheral venous blood as a result of mammographic breast compression
por: Förnvik, Daniel, et al.
Publicado: (2013)

Predicting pathological axillary lymph node status with ultrasound following neoadjuvant therapy for breast cancer
por: Skarping, Ida, et al.
Publicado: (2021)

Mammographic screening detects low-risk tumor biology breast cancers
por: Drukker, C. A., et al.
Publicado: (2014)

Coagulation/fibrinolysis and circulating tumor cells in patients with advanced breast cancer
por: Dirix, Luc Y., et al.
Publicado: (2022)

High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer
por: Nilsson, Martin P., et al.
Publicado: (2014)

Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial
por: Larsson, Anna-Maria, et al.
Publicado: (2018)

Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease
por: Olsson, Eleonor, et al.
Publicado: (2015)

Contralateral breast cancer can represent a metastatic spread of the first primary tumor: determination of clonal relationship between contralateral breast cancers using next-generation whole genome sequencing
por: Alkner, Sara, et al.
Publicado: (2015)

The mutational landscape of the SCAN‐B real‐world primary breast cancer transcriptome
por: Brueffer, Christian, et al.
Publicado: (2020)

Preexisting Somatic Mutations of Estrogen Receptor Alpha (ESR1) in Early-Stage Primary Breast Cancer
por: Dahlgren, Malin, et al.
Publicado: (2021)

Clinical Value of RNA Sequencing–Based Classifiers for Prediction of the Five Conventional Breast Cancer Biomarkers: A Report From the Population-Based Multicenter Sweden Cancerome Analysis Network—Breast Initiative
por: Brueffer, Christian, et al.
Publicado: (2018)

Circulating serum xenoestrogens and mammographic breast density
por: Sprague, Brian L, et al.
Publicado: (2013)

Clinical associations of ESR2 (estrogen receptor beta) expression across thousands of primary breast tumors
por: Dalal, Hina, et al.
Publicado: (2022)

Mammographic density as an image-based biomarker of therapy response in neoadjuvant-treated breast cancer patients
por: Skarping, Ida, et al.
Publicado: (2020)

A novel method for downstream characterization of breast cancer circulating tumor cells following CellSearch isolation
por: Frithiof, Henrik, et al.
Publicado: (2015)

Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer
por: Skarping, Ida, et al.
Publicado: (2019)

A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation
por: Frithiof, Henrik, et al.
Publicado: (2016)

Heterogeneity of Circulating Tumor Cells in Neoadjuvant Chemotherapy of Breast Cancer
por: Kaigorodova, Evgeniya V., et al.
Publicado: (2018)

Mammographic density changes during neoadjuvant breast cancer treatment: NeoDense, a prospective study in Sweden
por: Skarping, Ida, et al.
Publicado: (2020)

Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer
por: Dirix, Luc, et al.
Publicado: (2022)

The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers
por: Obdeijn, Inge-Marie, et al.
Publicado: (2020)

Expression of epithelial-mesenchymal transition-related markers and phenotypes during breast cancer progression
por: Jørgensen, Charlotte Levin Tykjær, et al.
Publicado: (2020)

The Distribution of Circulating Tumor Cells Is Different in Metastatic Lobular Compared to Ductal Carcinoma of the Breast—Long-Term Prognostic Significance
por: Narbe, Ulrik, et al.
Publicado: (2020)

Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort
por: Jansson, Sara, et al.
Publicado: (2016)

The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery
por: Collarino, Angela, et al.
Publicado: (2018)

Prediagnostic circulating metabolites in female breast cancer cases with low and high mammographic breast density
por: Bendinelli, Benedetta, et al.
Publicado: (2021)

Molecular characterization of circulating tumor cells from patients with metastatic breast cancer reflects evolutionary changes in gene expression under the pressure of systemic therapy
por: Aaltonen, Kristina E., et al.
Publicado: (2017)

Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients
por: Goorts, Briete, et al.
Publicado: (2017)

Matched analysis of circulating selenium with the breast cancer selenotranscriptome: a multicentre prospective study
por: Demircan, Kamil, et al.
Publicado: (2023)

Analysis of Circulating Tumor DNA to Predict Neoadjuvant Therapy Effectiveness and Breast Cancer Recurrence
por: Hao, Shuai, et al.
Publicado: (2020)

Characterization of circulating tumor cells in early breast cancer patients receiving neoadjuvant chemotherapy
por: Jakabova, Anna, et al.
Publicado: (2021)

Breast cancer pathology and stage are better predicted by risk stratification models that include mammographic density and common genetic variants
por: Evans, D. Gareth R., et al.
Publicado: (2019)

Circulating tumor cells and circulating tumor DNA in breast cancer diagnosis and monitoring
por: ALEMZADEH, EFFAT, et al.
Publicado: (2023)

Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status
por: Nilsson, Martin P., et al.
Publicado: (2014)

The Sweden Cancerome Analysis Network - Breast (SCAN-B) Initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine
por: Saal, Lao H, et al.
Publicado: (2015)

Evaluation of the Effects of Different Dietary Patterns on Breast Cancer: Monitoring Circulating Tumor Cells
por: Wang, Xiuxiu, et al.
Publicado: (2021)

Circulating tumor cells in breast cancer
por: Pukazhendhi, Geetha, et al.
Publicado: (2014)

Circulating tumor cells in breast cancer
por: Bidard, Francois-Clement, et al.
Publicado: (2016)

Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy
por: Kim, Ji-Yeon, et al.
Publicado: (2017)

Analysis of the serial circulating tumor cell count during neoadjuvant chemotherapy in breast cancer patients
por: Gwark, Sungchan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8pbg6dic9pi00c9f65q3u2bdo1